Gilead Sciences (NASDAQ:GILD) Given New $165.00 Price Target at Citigroup

Gilead Sciences (NASDAQ:GILD) had its price objective lifted by investment analysts at Citigroup from $156.00 to $165.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price target suggests a potential upside of 19.81% from the stock’s current price.

Several other research analysts have also recently issued reports on GILD. The Goldman Sachs Group upped their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Thursday, January 8th. Wolfe Research upped their price objective on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Jefferies Financial Group initiated coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective for the company. Royal Bank Of Canada upped their price objective on Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $156.77.

Gilead Sciences Stock Down 0.9%

NASDAQ GILD traded down $1.28 during trading hours on Monday, hitting $137.71. 1,599,717 shares of the company were exchanged, compared to its average volume of 6,964,537. The company has a 50 day moving average of $145.13 and a two-hundred day moving average of $130.59. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. Gilead Sciences has a 52-week low of $93.37 and a 52-week high of $157.29. The firm has a market cap of $170.93 billion, a price-to-earnings ratio of 20.32, a PEG ratio of 1.85 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the prior year, the business earned $1.90 EPS. Gilead Sciences’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts anticipate that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. This represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. The trade was a 1.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 299,280 shares of company stock valued at $42,820,550 in the last 90 days. Company insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

A number of large investors have recently modified their holdings of GILD. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences in the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its stake in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares in the last quarter. Corundum Trust Company INC purchased a new position in Gilead Sciences in the 3rd quarter valued at approximately $26,000. Quattro Advisors LLC purchased a new position in Gilead Sciences in the 4th quarter valued at approximately $26,000. Finally, Wealth Preservation Advisors LLC increased its stake in Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 81 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.